US Pharma MarketingGLP-1 boom pushes oncology off top spot for late-stage pipeline value: Deloitte
For the first time in its 16-year analysis of the pharma industry, Deloitte found obesity drugs are the largest contributor to late-stage pipeline value, overtaking longtime leader oncology.
For the first time in its 16-year analysis of the pharma industry, Deloitte found obesity drugs are the largest contributor to late-stage pipeline value, overtaking longtime leader oncology.
Source: FiercePharma